Therefore, our results suggest that instead of ablation of both tumor‐suppressive and oncogenic receptor activities, the reversal of the EphA2 oncogenic signaling switch may better correlate with effective HGSC sensitization to platinum‐based chemotherapy. The gene discussed is EPHA2; the disease is neoplasm.